BioNTech Buys Speed in Washington While Fighting Fires in Ottawa and Tokyo

BioNTech has put a $205 million price tag on regulatory speed. On Tuesday the German drugmaker agreed to buy an FDA Priority Review Voucher from Scholar Rock, paying entirely in cash, with the voucher earmarked to back a future marketing application from its late-stage oncology pipeline. It is a bet that shaving time off a review is worth more than the money spent to secure it — and a reminder that the company's next chapter will be judged on filings, not forecasts.

The deal landed alongside a busier legal calendar. Arbutus Biopharma and Genevant expanded their Canadian patent suit against Pfizer and BioNTech on Tuesday, adding a newly granted LNP patent to an action that already names BioNTech as a defendant. The plaintiffs are seeking financial compensation and injunctions. The same pair also filed two patent lawsuits in Japan, those aimed at Pfizer Japan.

A Quarter That Cut Both Ways

The financial backdrop is a company in transition. BioNTech reported third-quarter 2026 revenue of €1.289 billion, a decline year on year that management attributed chiefly to expected weaker demand for COVID-19 vaccines. Net profit for the period came in at €184.5 million. As of September 30, cash, cash equivalents and marketable securities stood at €16.2 billion — a war chest that comfortably covers both the voucher purchase and the cost of litigation.

Guidance moved in the opposite direction to sales. BioNTech raised the floor of its 2026 revenue forecast, lifting the range from €1.6–1.9 billion to €1.7–1.9 billion. Shares, however, slipped 2.7% on the day.

The Internal Bill for the Overhaul

Less visible than the courtroom filings is the friction inside the company. According to media reports, the works council sent a letter to the management board criticizing how employees are being handled through the transformation. Tuesday's coverage also pointed to roughly 40 job cuts following failed negotiations, concentrated in Mainz as well as Berlin and Munich, and referenced earlier layoffs in the low three-digit range at the Mainz site, particularly in IT.

For investors, that organizational strain belongs in the same ledger as the oncology spending. A strategic direction gains credibility when management carries the workforce through the change, and the works council's criticism argues for watching whether the friction proves persistent.

Three Ledgers, One Story

Read together, the vaccine decline, the oncology outlay and the internal restructuring form a single test of execution. The voucher only pays off if a filing follows; the raised revenue floor only holds if the core business stabilizes; and the transformation only convinces if management brings its employees along. That is the yardstick on which progress will be measured.